Loading company…
Third Arc Bio develops multifunctional antibodies designed to engage T cells in solid tumors and inflammatory and immunology diseases.
Founded in 2021 by Sanjaya Singh, Third Arc Bio develops antibody therapies for solid tumors and inflammatory and immunology diseases. Its antibodies are designed to activate or inhibit T cells through targeted immune synapses. In February 2026, the company raised USD 52 million in Series A funding led by Andreessen Horowitz, with participation from Galapagos NV and returning investors Goldman Sachs Asset Management, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures, Omega Funds, Vida Ventures, Cormorant Asset Management, Hillhouse Investment, and Alderline Group. The round was part of larger USD 217 million Series A funding. The proceeds will support its drug portfolio and early clinical studies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in